Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

443
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
443
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

420
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
420
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

409
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
409
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.7K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

584
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
584

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The kinetic parameters of dynamic contrast-enhanced MRI with ultrafast imaging in breast cancer patients receiving neoadjuvant chemotherapy: Prediction of pathologic complete response and correlation with histologic microvessel density.

Medicine·2025
Same author

The utility of ultrafast MRI and conventional DCE-MRI for predicting histologic aggressiveness in patients with breast cancer.

Acta radiologica (Stockholm, Sweden : 1987)·2024
Same author

Artificial intelligence for ultrasound microflow imaging in breast cancer diagnosis.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2024
Same author

MRI-based breast cancer radiogenomics using RNA profiling: association with subtypes in a single-center prospective study.

Breast cancer research : BCR·2023
Same author

Association between vascular ultrasound features and DNA sequencing in breast cancer: a preliminary study.

Discover oncology·2023
Same author

Scoring System to Predict Malignancy for MRI-Detected Lesions in Breast Cancer Patients: Diagnostic Performance and Effect on Second-Look Ultrasonography.

Taehan Yongsang Uihakhoe chi·2022
Same journal

Correction: Assalve et al. Marine Algal Metabolites as Cellular Antioxidants: A Study of Caulerpin and Caulerpinic Acid in <i>Saccharomyces cerevisiae</i>. <i>Mar. Drugs</i> 2025, <i>23</i>, 338.

Marine drugs·2026
Same journal

Laurinterol, the Main <i>Smart Secondary Metabolite</i> Among Lauranes and Cyclolauranes.

Marine drugs·2026
Same journal

Red Light Enhances Biomass and Bioactive Compounds Through Photosynthetic Acclimation in <i>Anabaena variabilis</i>.

Marine drugs·2026
Same journal

Seaweed-Derived Extract Targets Porphyr'ageing to Modulate the Visible Signs of Aging in Human Skin.

Marine drugs·2026
Same journal

The Potential and Prospects of Marine Drugs in Intervening Nerve-Tumor Crosstalk.

Marine drugs·2026
Same journal

Amylimycins A-C, New Bacillomycin D Analogs from Marine-Derived <i>Bacillus amyloliquefaciens</i>.

Marine drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 6, 2026

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing
04:09

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Published on: December 13, 2024

1.2K

Therapies from Fucoidan: New Developments.

Helen J Fitton1, Damien S Stringer2, Ah Young Park2

  • 1Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia. helen.fitton@marinova.com.au.

Marine Drugs
|October 12, 2019
PubMed
Summary
This summary is machine-generated.

Fucoidan research has expanded since 2015, with new clinical applications for renal disease and thrombi imaging. Emerging uses include microbiome modulation and anti-pathogenic effects, offering alternatives to antibiotics.

Keywords:
analysisfucoidanmicrobiomenorovirus

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.6K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.0K

Related Experiment Videos

Last Updated: Jan 6, 2026

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing
04:09

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Published on: December 13, 2024

1.2K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.6K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.0K

Area of Science:

  • Marine biotechnology
  • Pharmacology
  • Biomedical research

Background:

  • Fucoidan, a sulfated polysaccharide from brown algae, has shown diverse biological activities.
  • Previous research highlighted fucoidan's potential, prompting further investigation.
  • Significant advancements in fucoidan research have occurred since 2015.

Purpose of the Study:

  • To review recent developments in fucoidan research and applications.
  • To highlight novel therapeutic and diagnostic uses of fucoidan.
  • To discuss the potential of fucoidan as an alternative to antibiotics.

Main Methods:

  • Literature review of studies published since 2015.
  • Analysis of clinical trials and safety studies.
  • Examination of new analytical techniques for fucoidan assessment.

Main Results:

  • Clinical fucoidan use for renal disease is now available.
  • Human safety studies for radiolabeled fucoidan in thrombi imaging have been conducted.
  • Fucoidan is increasingly used in supplements and topical treatments.
  • New techniques enhance fucoidan uptake assessment and production.
  • Fucoidan shows promise for microbiome modulation and anti-pathogenic effects.

Conclusions:

  • Fucoidan research has broadened significantly, with established and emerging clinical applications.
  • Fucoidan offers promising alternatives to conventional antibiotic use, particularly in the food chain.
  • Future therapeutic potential for fucoidan is substantial across various medical fields.